Non-alcoholic Steatohepatitis Market Size, Trends, Analysis, and Outlook By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy), by Region, Coun

Non-alcoholic Steatohepatitis Market Size, Trends, Analysis, and Outlook By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy), by Region, Country, Segment, and Companies, 2024-2030

The global Non-alcoholic Steatohepatitis market size is poised to register 44.2% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Non-alcoholic Steatohepatitis market By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy).
The future of non-alcoholic steatohepatitis (NASH) is shaped by advancements in hepatology, molecular biology, and precision medicine aimed at improving disease diagnosis, risk stratification, and therapeutic interventions for patients with this progressive form of fatty liver disease. Key trends include the development of NASH-specific biomarkers, imaging modalities, and non-invasive fibrosis assessments that enable accurate disease staging, monitoring of disease progression, and prediction of clinical outcomes in affected individuals. Additionally, there is a growing emphasis on the integration of targeted pharmacotherapies, such as apoptosis signal-regulating kinase 1 (ASK1) inhibitors, cenicriviroc (CVC), and obeticholic acid (OCA), into NASH treatment algorithms to address hepatic inflammation, fibrosis regression, and metabolic dysfunction associated with the disease. Moreover, advancements in patient-centered care models, multidisciplinary treatment teams, and patient education programs facilitate holistic management approaches, lifestyle modifications, and long-term adherence to therapeutic regimens in NASH patients, driving continuous innovation and adoption of NASH therapies in hepatology practice, clinical research, and pharmaceutical development pipelines..

Non-alcoholic Steatohepatitis Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Non-alcoholic Steatohepatitis market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Non-alcoholic Steatohepatitis survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Non-alcoholic Steatohepatitis industry.

Key market trends defining the global Non-alcoholic Steatohepatitis demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Non-alcoholic Steatohepatitis Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Non-alcoholic Steatohepatitis industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Non-alcoholic Steatohepatitis companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Non-alcoholic Steatohepatitis industry
Leading Non-alcoholic Steatohepatitis companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Non-alcoholic Steatohepatitis companies.

Non-alcoholic Steatohepatitis Market Study- Strategic Analysis Review
The Non-alcoholic Steatohepatitis market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

• Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
• Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
• Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
• Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Non-alcoholic Steatohepatitis Market Size Outlook- Historic and Forecast Revenue in Three Cases
The Non-alcoholic Steatohepatitis industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Non-alcoholic Steatohepatitis Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Non-alcoholic Steatohepatitis Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Non-alcoholic Steatohepatitis market segments. Similarly, Strong end-user demand is encouraging Canadian Non-alcoholic Steatohepatitis companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Non-alcoholic Steatohepatitis market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Non-alcoholic Steatohepatitis Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Non-alcoholic Steatohepatitis industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Non-alcoholic Steatohepatitis market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Non-alcoholic Steatohepatitis Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Non-alcoholic Steatohepatitis in Asia Pacific. In particular, China, India, and South East Asian Non-alcoholic Steatohepatitis markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Non-alcoholic Steatohepatitis Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Non-alcoholic Steatohepatitis Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Non-alcoholic Steatohepatitis market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Non-alcoholic Steatohepatitis.

Non-alcoholic Steatohepatitis Market Company Profiles
The global Non-alcoholic Steatohepatitis market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AstraZeneca Plc, BioPredictive S.A.S, Cirius Therapeutics, Enzo Biochem Inc, GENFIT SA, Gilead Sciences Inc, GlaxoSmithKline Plc, Intercept Pharmaceuticals Inc, Inventiva S.A., Madrigal Pharmaceuticals Inc, Novo Nordisk AS, Prometheus Laboratories, Siemens Healthineers AG.

Recent Non-alcoholic Steatohepatitis Market Developments
The global Non-alcoholic Steatohepatitis market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Non-alcoholic Steatohepatitis Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis

• Pricing Analysis
• Value Chain Analysis
• SWOT Profile
• Market Dynamics- Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• Macroeconomic Impact Analysis
• Case Scenarios- Low, Base, High

Market Segmentation:

By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound

By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems

By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others

By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others

Geographical Segmentation:

• North America (3 markets)
• Europe (6 markets)
• Asia Pacific (6 markets)
• Latin America (3 markets)
• Middle East Africa (5 markets)

Companies
AstraZeneca Plc
BioPredictive S.A.S
Cirius Therapeutics
Enzo Biochem Inc
GENFIT SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
Inventiva S.A.
Madrigal Pharmaceuticals Inc
Novo Nordisk AS
Prometheus Laboratories
Siemens Healthineers AG

Formats Available: Excel, PDF, and PPT